drugset

drugset / Trial / NCT00622063

An Extension Study for Patients Previously Treated With ARQ 501

NCT00622063 ↗

Phase 1/2 Completed 1 enrolled ArQule, Inc.

NaSingle-groupOpen-labelTreatment

Summary

To provide ongoing treatment with ARQ 501 for patients who have benefited from prior treatment with ARQ 501

Timeline

Start: 2006-12
Primary completion: 2008-09
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LAPACHONE	Small molecule	—	—

Indications